Bactrim is a widely registered sulfonamide combination, marketed in 35 countries across both established and emerging healthcare markets. Its active ingredients are sulphamethoxazole and trimethoprim, two antibacterial molecules paired within a single oral preparation and classified together as a sulfonamide combination.
The combination is prescribed for a range of bacterial infections, including urinary tract infections, certain types of pneumonia, shigellosis, and enteritis, as well as for the prevention of specific infections in patients at higher risk. The two ingredients act on sequential steps of the same bacterial pathway, which is why they have been formulated together rather than prescribed individually — a pairing that has been a backbone of antibacterial therapy for decades. The structured indication list further down this page details the registered uses recognised in the markets where Bactrim is sold.
Because Bactrim has such a broad international footprint, travellers and expatriates frequently encounter the same combination abroad, sometimes labelled as Bactrim and sometimes under other brand names or as a generic sulphamethoxazole-trimethoprim product. Markets where the brand is registered include Brazil, Italy, Australia, Indonesia, and Lebanon, but regulatory status, packaging, and prescription pathways differ considerably from one country to another. A pharmacist in the destination market can confirm whether a locally available sulphamethoxazole-trimethoprim product corresponds to what the patient is used to.
Other antibacterial agents are available worldwide for overlapping indications, but antibiotic choice is rarely a like-for-like substitution — it depends on the type of infection, the patient's history, and regional resistance patterns. Any change to antibacterial therapy, whether at home or while travelling, belongs in the hands of a prescribing healthcare provider.
